Advances in Anticancer Drug Discovery: Exploring the Untapped Potential of Natural Products for Targeted Therapies

Natural products have long been a significant source of structurally diverse and biologically active compounds, making them important for anticancer drug development. Taxol, a natural product isolated from the bark of the Pacific yew tree, is used to treat some cancers; Vincristine, a related compound that was eked out of the Madagascar periwinkle plant, treats leukemia and lymphoma. This review provides recent advances and future perspectives on developing natural-product-derived anticancer agents. We introduce celebrated examples of successfully developed natural-product-derived anticancer drugs, such as paclitaxel, doxorubicin, and camptothecin derivatives. We also discuss the hurdles of natural product-derived drug discovery, including limited availability, poor pharmacokinetics, and a lack of specificity to their intended targets.

We will talk about some examples of these types of modification, including new developments in drug delivery systems, nanotechnology, and targeted drug delivery. These show how they could make natural product-derived anti-tumor drugs more effective and less harmful. It is emphasized that researchers from different fields, such as pharmacologists, catalyst chemists, drug delivery experts, rational drug designers, and nanotechnologists, will need to work together and research across disciplines for the project to succeed. This is so that problems and bottlenecks can be solved, and natural products can be used to make new anticancer drugs. Given the continuous and increasing global demand for novel anticancer drugs in the foreseeable future, natural products will remain a critically important source for discovering novel, safe, and effective anticancer drugs.